TCT-448 Transcatheter aortic valve replacement for isolated severe native aortic valve regurgitation – results from the TAVR-NAVR Registry

Pilgrim, Thomas; Søndergaard, Lars; Santos, Matheus Simonato dos; Mackensen, G. Burkhard; Cerillo, Alfredo Giuseppe; Schöfer, Joachim; Amabile, Nicolas; Achkouty, Guy; Schäfer, Ulrich; Deutsch, Marcus-André; Sinning, Jan‐Malte; Hildick‐Smith, David; Mieghem, Nicolas Van; Windecker, Stephan; Kim, Won; Lefèvre, Thierry; Seiffert, Moritz; Bleiziffer, Sabine; Petronio, Anna Sonia; Taramasso, Maurizio; Latib, Azeem; Dvir, Danny

doi:10.1016/j.jacc.2017.09.556

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The initial search revealed a total of 5,208 potential articles. After exclusions, 19 reports remained for analysis (13 full texts , and 6 conference abstracts ). The PRISMA flow chart (Figure ) gives an overview of the literature search.…”

Section: Resultsmentioning

confidence: 99%

Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta‐analysis

Rawasia

Khan

Usman

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objective: The objective of this study was to analyze the available literature on using transcatheter aortic valve replacement (TAVR) for native aortic regurgitation (AR).Background: Surgical aortic valve replacement is the gold standard therapy for native AR. TAVR has emerged as an alternative approach in high-risk patients.Methods: MEDLINE, Scopus, and Cochrane CENTRAL were searched for reports of at least 5 patients undergoing TAVR for native AR. Outcomes included 30-day mortality, myocardial infarction, stroke, major bleeding, postprocedural moderate to severe AR, and device success.Pooled estimates were calculated using a random-effects model. Subgroup analysis and a metaregression were performed to study the effects of study level covariates on outcomes.Results: Nineteen studies (n =998 patients) were included. The rate of procedural success per Valve Academic Research Consortium -2 (VARC-2) criteria was 86.2% (78.8%-92.2%]. Thirty-day mortality was 11.9% (9.4%-14.7%). Subgroup analysis showed the use of new generation valves was associated with lower 30-day mortality (P = 0.02) and higher device success (P = 0.009) compared with early generation valves. There was no significant difference (P = 0.13) in the rate of 30-day mortality between patients receiving purpose-specific [8.2% (4.3%−13.1%); I2 = 0%] and nonpurpose specific valves [13.0% (8.2%-18.6%); I2 = 25%]. However, device success was higher (P = 0.02) in patients who received purpose-specific valves [96.3% (92.2%−98.9%); I2 = 0%] compared with nonpurpose specific valves [84.4% (75%−91.9%); I2 =46%].Conclusion: TAVR for native AR is associated with acceptable procedural success but increased early mortality. However, the safety and the efficacy of the procedure increased with newer valves. K E Y W O R D Saortic valve insufficiency, heart diseases, heart valve prosthesis

show abstract

Section: Resultsmentioning

confidence: 99%

Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta‐analysis

Rawasia

Khan

Usman

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…We were able to identify three reports that met our inclusion criteria but had to be excluded from the analysis due to study centers overlap with other included studies and the risk of data inflation. [17][18][19] Finally, 12 studies were identified as eligible and included in our systematic review [20][21][22][23][24][25][26][27][28][29][30][31] (Figure 1). In total, 638 patients with native pure aortic regurgitation identified across the 12 studies.…”

Section: Resultsmentioning

confidence: 99%

“…The incidence rate of cerebrovascular accidents in our analysis was 2% with no significant difference between first and second generation valves, compared to 5% at 30 days and 7.8% at 1 year in PART-NER trial. 37 The rate of embolism, including transient ischemic 18,24,30 Additionally, these features could explain the higher device success rate in second generation valves when compared to first generation, 92% vs 68%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Transcatheter aortic valve replacement in patients with pure native aortic valve regurgitation: A systematic review and meta‐analysis

Haddad

Arwani

Altayar

et al. 2018

Clinical Cardiology

View full text Add to dashboard Cite

This systematic review and meta‐analysis sought to summarize the available evidence on the use of transcatheter aortic valve replacement (TAVR) in patients with Native Aortic Valve Regurgitation (NAVR) and compare outcomes between first and second generation valves. Owing to the improvements in transcatheter heart valve design and procedural success, TAVR has become increasingly performed in broader aortic valve pathologies. We searched Medline, Embase, Cochrane, and Scopus databases from 2007 to 2018 and performed a systematic review on reports with at least 10 patients with aortic valve regurgitation undergoing TAVR procedure. The main outcome of interest was all‐cause mortality at 30 days. A total of 638 patients across 12 studies were included. Mean age ranged from 68 to 84. Society of Thoracic Surgeons score ranged from 5.4% to 13.1% and Logistic EuroSCORE ranged from 18.2% to 33%. The incidence rate of all‐cause mortality at 30 days was found to be 11% (95% CI 7%‐16%; I2 = 20.86%). All‐cause mortality at 30 days for first generation valves had an incidence rate of 15% (95% CI 10%‐20%; I2 = 10%) compared to 7% (95% CI 3%‐13%; I2 = 37%) in second generation valves with subgroup interaction analysis P = 0.059. Device success incidence rate in second generation valves was 92% (95% CI 83%‐99%; I2 = 67%) vs 68% (95% CI 59%‐77%; I2 = 53%) in first generation valves with P = 0.001. TAVR appears to be a feasible treatment choice for NAVR patients at high risk for surgical valve replacement. Second generation valves show promising results in terms of short‐term outcomes.

show abstract

Transcatheter aortic valve replacement for aortic regurgitation: a systematic review and meta‐analysis

Liu,

Fu,

Jiang

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

The efficacy and safety of new‐generation devices (NGDs) for severe aortic regurgitation (AR) have mostly been based on single‐arm studies with limited sample sizes. Our goal was to summarize the current evidence on NGDs and compare the safety and efficacy of ‘off‐label’ and ‘on‐label’ devices in NGDs. We searched MEDLINE, Embase, Cochrane Library, and Scopus for articles on transcatheter aortic valve replacement in patients with AR. A total of 31 studies that included 1851 patients were identified through April 2023. Among these, 1067 (57.6%) patients received treatment with ‘on‐label’ devices (JenaValve and J‐Valve). For NGDs, the total device success rate at 30 days was 94.5% (on‐label: 97.8%, off‐label: 89.9%; P < 0.001), the all‐cause mortality was 4.2% (on‐label: 2.6%, off‐label: 5.1%; P = 0.006), permanent pacemaker implantation (PPI) was 8.8% (on‐label: 6.9%, off‐label: 18.4%; P < 0.001), and the rate of greater‐than‐mild paravalvular leak (PVL) was 1.2% (on‐label: 0.9%, off‐label: 3.8%; P = 0.003). On‐label devices showed significantly better safety and efficacy in terms of the success rate, PPI, greater‐than‐mild PVL, and 30 day mortality than off‐label devices.

show abstract

TCT-448 Transcatheter aortic valve replacement for isolated severe native aortic valve regurgitation – results from the TAVR-NAVR Registry

Cited by 5 publications

References 0 publications

Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta‐analysis

Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta‐analysis

Transcatheter aortic valve replacement in patients with pure native aortic valve regurgitation: A systematic review and meta‐analysis

Transcatheter aortic valve replacement for aortic regurgitation: a systematic review and meta‐analysis

Contact Info

Product

Resources

About